Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: A cost-effectiveness analysis from a U.S. perspective

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 303-310

  Pishko, Allyson M ^a   Smith, Kenneth J ^a   Ragni, Margaret V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Hemophilia Center of Western PA   (United States)

Author keywords

Anticoagulation; Cancer; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN;

AMBULATORY CARE; ANTICOAGULATION; BIOLOGICAL MODEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; HUMAN; LIFE EXPECTANCY; LUNG EMBOLISM; MARKOV MODEL; METASTASIS; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VENOUS THROMBOEMBOLISM;

AMBULATORY CARE; ANTICOAGULANTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, THEORETICAL; NEOPLASMS; PROBABILITY; REVIEW LITERATURE AS TOPIC; RISK; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84864343446     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0185     Document Type: Review

References (28)

1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
2. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna cancer and thrombosis study (CATS). Blood 2008; 112: 2703-2708.
3. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study. J Clin Oncol 2009; 27: 4124-4129.
4. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anti-coagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 4902-4911.
5. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-1524.
6. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.
7. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
8. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000; 26 (Suppl 1): 69-77.
9. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
10. Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systemic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-1161.
11. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729-737.
12. Akl EA, Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival or patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008; 27: 1-10.
13. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; 6: CD006649, 1-59.
14. th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 14: (Suppl): e195S-226S.
15. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guideline panels and call to action. J Clin Oncol 2009; 27: 4919-4926.
16. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomized, placebo-controlled, doubleblind study. Lancet Oncol 2011; 10: 943-949.
17. Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011; 4: CD006652, 1-50.
18. Agnelli G, George JG, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-609.
19. Akl EA, Vasireddi SR, Gunukula S, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev2011; 6: CD006466, 1-39.
20. Aujesky D, Smith KJ, Robert MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005; 118: 625-635.
21. Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost 2005; 93: 592-599.
22. Prandoni P, Flanaga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
23. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
24. Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005; 128: 1601-1610.
25. Red Book: Pharmacy's Fundamental Reference. Thomson Health Care, Montvale NJ, 2010.
26. Healthcare Cost and Utilization Project (HCUP) 2009. Agency for Healthcare Research and Quality (AHRQ). Available at: http://hcupnet.ahrq.gov. Accessed January 31, 2012.
27. Braithwaite RS, Meltzer DO, King JT, Jr. et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-356.
28. Ageno W, Squizzato A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-750.